Market News & Trends
BriaCell Secures License for Promising Novel Anti-Cancer Agent
BriaCell Therapeutics Corp. recently announced it has secured an exclusive license from University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80)…
US Patent Issued to HCW Biologics for Foundational Platform Technology
HCW Biologics Inc. was granted US Patent No. 11,401,324, which contains claims for immunotherapeutic compounds comprised of a single-chain chimeric polypeptide with two target-binding domains…
Ocuphire Extends US Patent Protection for Late-Stage Drug Candidate for Reversal of Mydriasis by 5 More Years Into 2039
Ocuphire Pharma, Inc. recently announced the issuance of US Patent No. 11,400,077. The patent provides added intellectual property protection for the company’s late-stage product candidate,…
Athira Pharma Presents Data From ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients
Athira Pharma, Inc. recently announced Hans Moebius, MD, PhD, Athira’s Chief Medical Officer, is leading an oral presentation titled ACT-AD: Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease…
Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial
Cornerstone Pharmaceuticals, Inc. recently announced the successful completion of a Phase 1b clinical trial of CPI-613 (devimistat) in combination with gemcitabine and cisplatin for the treatment…
Context Therapeutics & The Menarini Group Announce Clinical Trial Collaboration & Supply Agreement
Context Therapeutics Inc. and The Menarini Group recently announced a clinical trial collaboration and supply agreement for Menarini’s oral selective estrogen receptor degrader (SERD), elacestrant.…
Curia Appoints Niall Condon to Lead Manufacturing
Curia recently announced the appointment of Niall Condon as President of its Manufacturing Division, with immediate effect. Condon will drive growth and be responsible for…
Enteris BioPharma Announces Acceptance of Abstract for Oral Presentation at ASRM 2022 Scientific Congress & Expo
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq:…
Verrica Pharmaceuticals Announces Start of Phase 3 Trial for the Treatment of Molluscum Contagiosum
Verrica Pharmaceuticals Inc. recently announced Torii Pharmaceutical Co., Ltd. dosed the first patient in its Phase 3 trial of VP-102 (referred to as TO-208 in…
Akari Therapeutics Narrows Pipeline Focus
Akari Therapeutics, Plc recently announced it is prioritizing two pipeline programs. Cash and resources will be reallocated to the Phase 3 clinical trial of nomacopan…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….